9 Myths About Menopause and Sexual Desire That Are Hurting Women and Their Relationships
The thing that stings most about this particular cluster of myths is how many women blame themselves — or let their partners believe the relationship is the problem — when the real story is just hormones and a medical system that hasn't talked openly enough about solutions. This is one of those areas where good information can change everything, fast.
Learn more about Rose →Myth: Loss of libido during menopause is inevitable and permanent
While hormonal shifts — particularly declining estrogen and testosterone — do affect sexual desire in many women, this is not a universal or irreversible outcome. Large population studies, including the Study of Women's Health Across the Nation (SWAN), show significant variation: many women report no change or even increased desire after menopause, often linked to freedom from contraception concerns and reduced anxiety around pregnancy. The key word is 'can affect,' not 'will destroy' — and where desire does decline, effective interventions exist.
Myth: Desire problems in midlife are psychological, not physical
This myth does real harm because it sends women to therapy for a problem that has a measurable biological mechanism. Estrogen receptors are found throughout the vulva, vagina, and clitoris; as estrogen falls, blood flow to genital tissue decreases, sensitivity can diminish, and the neurochemical pathways that support arousal are genuinely disrupted. Testosterone, which also declines in the perimenopause years, is a key driver of sexual motivation in women — its drop is physiological, not imagined.
Myth: If sex is painful, desire loss is just a natural consequence — not a separate, treatable problem
Genitourinary Syndrome of Menopause (GSM), which includes vaginal dryness, thinning tissues, and pain during sex, is estimated to affect up to 60% of postmenopausal women and is directly driven by estrogen loss. Pain during sex reliably conditions the brain to reduce desire — a learned protective response — so what looks like low libido is often the downstream result of an untreated physical problem. Treating GSM with local estrogen or other licensed therapies frequently restores both comfort and desire without any systemic hormone exposure.
Myth: Testosterone is a 'male hormone' and has no role in women's sexual health
Testosterone is produced by women's ovaries and adrenal glands throughout their lives and plays a well-documented role in libido, arousal, and sexual satisfaction. Levels begin declining in the late reproductive years and drop further around menopause, and multiple randomized controlled trials have demonstrated that testosterone therapy improves sexual function in postmenopausal women with hypoactive sexual desire disorder (HSDD). The 2019 Global Consensus Position Statement on testosterone in women, endorsed by major menopause societies worldwide, concluded the evidence for its use is robust.
Myth: HRT will fix everything, so there's no need to address desire separately
Systemic hormone replacement therapy (HRT) containing estrogen and progestogen reliably improves many menopause symptoms, and by reducing hot flashes, improving sleep, and relieving vaginal dryness it can indirectly help sexual function. However, research consistently shows that estrogen alone does not reliably restore libido in women whose primary complaint is loss of sexual desire — testosterone addresses a different hormonal pathway, and desire often needs to be treated specifically. Women reporting low libido on HRT should not assume they have simply run out of options.
Myth: Talking to a doctor about low libido is pointless — they'll just say it's normal aging
This myth is unfortunately grounded in some women's real experiences of being dismissed, but the medical landscape has shifted considerably. Hypoactive Sexual Desire Disorder (HSDD) is a recognized clinical diagnosis with published diagnostic criteria, and licensed treatment options — including testosterone therapy, local estrogen, ospemifene, and psychological interventions — are available and effective. Women who feel dismissed are entitled to push back, ask for a specialist referral, or seek a clinician with specific menopause training.
Myth: Desire changes only affect women who had a high libido to begin with
Sexual desire exists on a spectrum and is highly individual, but the hormonal mechanisms that underpin arousal, sensitivity, and motivation operate regardless of a woman's previous baseline. Women who describe themselves as never having had a particularly high sex drive can still experience a meaningful and distressing decline that is hormone-related, and the treatments shown to work in clinical trials are equally applicable to them. Distress about the change — not the baseline level — is what defines a clinically significant problem.
Myth: A partner's response to menopause symptoms has little effect on a woman's desire
This is the myth that does the most damage inside relationships. Research consistently shows that relationship quality, partner communication, and a partner's response to physical changes are among the strongest predictors of sexual satisfaction and desire maintenance during the menopause transition. A partner who is informed, patient, and willing to adapt sexually is protective against desire decline; a partner who is uninformed, pressuring, or who interprets changes as rejection creates a feedback loop that compounds the physiological problem. Couples-level education and communication are genuinely evidence-based interventions.
Myth: Women who seek treatment for low libido are prioritizing sex over more important health concerns
Sexual wellbeing is explicitly recognized by the World Health Organization as a component of overall health and quality of life, not a luxury add-on. Studies link sexual satisfaction in midlife to better mental health outcomes, stronger relationship stability, and improved self-reported wellbeing — the connections are bidirectional and real. A woman seeking help for lost desire is not being frivolous; she is doing exactly what any patient with a quality-of-life-affecting, treatable condition should do.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.